- Home
- SGBX vs QLGN Comparison
SGBX vs QLGN Comparison
Compare SGBX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGBX
- QLGN
- Stock Information
- Founded
- SGBX 2007
- QLGN 1996
- Country
- SGBX United States
- QLGN United States
- Employees
- SGBX N/A
- QLGN N/A
- Industry
- SGBX RETAIL: Building Materials
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SGBX Consumer Discretionary
- QLGN Health Care
- Exchange
- SGBX Nasdaq
- QLGN Nasdaq
- Market Cap
- SGBX 2.4M
- QLGN 2.2M
- IPO Year
- SGBX 2017
- QLGN N/A
- Fundamental
- Price
- SGBX $0.41
- QLGN $3.48
- Analyst Decision
- SGBX
- QLGN
- Analyst Count
- SGBX 0
- QLGN 0
- Target Price
- SGBX N/A
- QLGN N/A
- AVG Volume (30 Days)
- SGBX 227.6K
- QLGN 158.4K
- Earning Date
- SGBX 05-16-2025
- QLGN 05-06-2025
- Dividend Yield
- SGBX N/A
- QLGN N/A
- EPS Growth
- SGBX N/A
- QLGN N/A
- EPS
- SGBX N/A
- QLGN N/A
- Revenue
- SGBX $4,976,618.00
- QLGN N/A
- Revenue This Year
- SGBX $1,628.82
- QLGN N/A
- Revenue Next Year
- SGBX N/A
- QLGN N/A
- P/E Ratio
- SGBX N/A
- QLGN N/A
- Revenue Growth
- SGBX N/A
- QLGN N/A
- 52 Week Low
- SGBX $0.30
- QLGN $2.85
- 52 Week High
- SGBX $9.30
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- SGBX 47.75
- QLGN 52.85
- Support Level
- SGBX $0.34
- QLGN $3.10
- Resistance Level
- SGBX $0.39
- QLGN $4.40
- Average True Range (ATR)
- SGBX 0.04
- QLGN 0.40
- MACD
- SGBX 0.01
- QLGN 0.05
- Stochastic Oscillator
- SGBX 81.85
- QLGN 40.32
About SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.